Cheraghali A M, Abolghasemi H
Iranian Blood Transfusion Organization Research Center, Tehran, Iran.
Haemophilia. 2009 Mar;15(2):487-93. doi: 10.1111/j.1365-2516.2008.01936.x.
In 1974, the government of Iran established Iranian Blood Transfusion Organization (IBTO) as national and centralized transfusion system. Since then donations of blood may not be remunerated and therapy with blood and its components are free of charges for all Iranian patients. Donations are meticulously screened through interviewing donors and lab testing the donations using serological methods. Currently, Iranian donors donate 1735 00 units of blood annually (donation index: 25/1000 population). Implementation of a highly efficient donor selection programme, including donors interview, establishment of confidential unit exclusion programme and laboratory screening of donated bloods by IBTO have led to seroprevalence rates of 0.41%, 0.12% and 0.004% for HBV, HCV and HIV in donated bloods respectively. Since 2004, IBTO has initiated a programme to enter into a contract fractionation agreement for the surplus of recovered plasma produced in its blood collecting centres. Although IBTO has used this project as a mean to improve national transfusion system through upgrading its quality assurance systems, IBTO fractionation project has played a major role in improving availability of plasma-derived medicines in Iran. During 2006-2007, this project furnished the Iran market with 44% and 14% of its needs to the intravenous immunoglobulin and albumin, respectively. Iranian experience showed that contract fractionation of plasma in countries with organized centralized transfusion system, which lack national plasma fractionation facility, in addition to substantial saving on national health resource and enhancing availability of plasma-derived medicines, could serve as a useful means to improve national blood safety profile.
1974年,伊朗政府成立了伊朗输血组织(IBTO),作为国家集中输血系统。自那时起,献血不再给予报酬,所有伊朗患者接受血液及其成分的治疗均免费。通过对献血者进行访谈并使用血清学方法对献血进行实验室检测,对献血进行严格筛选。目前,伊朗献血者每年献血173.5万单位(献血指数:每千人口25次)。实施高效的献血者选择计划,包括献血者访谈、建立保密单位排除计划以及由IBTO对献血进行实验室筛查,使得献血中乙肝病毒(HBV)、丙肝病毒(HCV)和艾滋病毒(HIV)的血清流行率分别为0.41%、0.12%和0.004%。自2004年以来,IBTO启动了一项计划,就其采血中心产生的多余回收血浆签订合同分馏协议。尽管IBTO将该项目作为通过升级其质量保证系统来改善国家输血系统的一种手段,但IBTO分馏项目在提高伊朗血浆衍生药物的可及性方面发挥了重要作用。在2006 - 2007年期间,该项目分别满足了伊朗市场44%和14%的静脉注射免疫球蛋白和白蛋白需求。伊朗的经验表明,在缺乏国家血浆分馏设施的有组织的集中输血系统国家,对血浆进行合同分馏,除了能大幅节省国家卫生资源并提高血浆衍生药物的可及性外,还可作为改善国家血液安全状况的有效手段。